The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
 
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Ipsen; Merck; Novartis; Rafael Pharmaceuticals; Sanofi
Consulting or Advisory Role - Celgene; Gilead Sciences; Halozyme; Ipsen; Merck; Merrimack; novartis
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Celgene; Ipsen; Merck
Research Funding - Bayer (Inst); Genentech (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - Halozyme
 
Marc E. Buyse
Employment - IDDI
Stock and Other Ownership Interests - IDDI
 
Angela Tatiana Alistar
Consulting or Advisory Role - Celgene; Rafael Pharmaceuticals
Speakers' Bureau - Bristol-Myers Squibb; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; celgene; Rafa Pharmaceutical
 
Caio Max Sao Pedro Rocha Lima
Speakers' Bureau - Celgene
 
Sanjeev Luther
Employment - Rafael Pharmaceuticals
Leadership - Rafael Pharmaceuticals
Stock and Other Ownership Interests - Rafael Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Pending
Travel, Accommodations, Expenses - Rafael Pharmaceuticals
 
Timothy S. Pardee
Employment - Rafael Pharmaceuticals
Leadership - Rafael Pharmaceuticals
Honoraria - CBM Biopharma
Consulting or Advisory Role - CBM Biopharma
Speakers' Bureau - Amgen; Celgene; Novartis
Research Funding - Rafael Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Named on a provisional patent on the use of KPC34 for the treatment of acute leukemias.
Travel, Accommodations, Expenses - Celgene; Cornerstone Pharmaceuticals
 
Eric Van Cutsem
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)